1380079-58-2

Upstream product

• 192711-11-8 2-((tert-butyldimethylsilyl)oxy)-4-methoxybenzaldehyde 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 63558-07-6 N-(3,5-dibromo-4-hydroxyphenyl)acetamide 
• 41727-70-2 3,5-dibromo-4-methoxyaniline 
• 609-21-2 2,6-dibromo-4-aminophenol 
• 1363602-98-5 5-azido-1,3-dibromo-2-methoxybenzene 
• 1363603-16-0 tert-butyl(2-ethynyl-5-methoxyphenoxy)dimethylsilane 
• 673-22-3 2-Hydroxy-4-methoxybenzaldehyde 

Relevant academic research and scientific papers

Increased endothelial cell selectivity of triazole-bridged dihalogenated A-ring analogues of combretastatin A-1

The antiproliferative activity on ovarian cancer (SK-OV-3) cells of a series of triazole-bridged combretastatin analogues (37, 38, 40-43) containing dihalogenation of the A-ring is reported, and compared with their trimethoxy analogues (5, 15, 39). It was found that dihalogenation with either bromine or iodine was a tolerated modification when compared to the parent compound combretastatin (CA-4, 1) and had less effect than B-ring modification on potency. These compounds exhibited G2/M arrest, and maintained antitubulin activity. Further assays on human umbilical vein endothelial cells (HUVECs) demonstrated the potential antivascular effects of these triazoles. Of particular note was a 3,5-diiodo-4-methoxyaryl triazole (43) which had promising 7-fold selectivity for HUVECs over ovarian cancer cells.